Acrocinonide (or triamcinolone acroleinide) a glucocorticoid anti-inflammatory compound, which has never been marketed.

Clobetasone is a corticosteroid used in dermatology, for treating such skin inflammation as seen in eczema, psoriasis and other forms of dermatitis, and ophthalmology. Topical clobetasone butyrate has shown minimal suppression of the Hypothalamic-pituitary-adrenal axis. It is available as clobetasone butyrate under the brand names Eumosone or Eumovate both manufactured by GlaxoSmithKline. Trimovate also contains Oxytetracycline, an antibiotic, and nystatin, an antifungal. Clobetasone butyrate is classed as a moderately potent topical corticosteroid. Clobetasone butyrate relieves the symptoms of a flare-up by reducing inflammation, itching and redness. It is not a cure for the condition, but it will help to relieve the symptoms. Although less potent topical steriods are often preferred for use in children, a short course of clobetasone butyrate may be prescribed for a child with severe eczema on the arms or legs. Short courses of clobetasone butyrate may also be prescribed for the treatment of psoriasis for areas such as the face, or the inside of elbows and behind the knees. In ophthalmology, clobetasone butyrate 0.1% eye drops have been shown to be safe and effective in the treatment of dry eyes in Sjögren's Syndrome.

Oxymestereone is anabolic-androgenic steroid, a methylated derivative of testosterone. The drug was developed in 1960 and was in clinical use under brand names Oranabol, Anamidol, Balnimax, Sanabol, and Theranabol, however, it was discontinued later.

Fluticasone is a medium-potency synthetic trifluorinated corticosteroid which is used in some countries to manage nasal symptoms of allergic and non-allergic rhinitis. Fluticasone binds and activates glucocorticoid receptor, resulting in the activation of lipocortin. Lipocortin, in turn, inhibits cytosolic phospholipase A2, which triggers a cascade of reactions involved in the synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Both the furoate and propanoate esters, fluticasone furoate and fluticasone propionate, are much more commonly used as topical anti-inflammatories and inhaled corticosteroids.

EPIMESTROL is a synthetic steroid with estrogenic activity. It was used for the treatment of chronic anovulation and corpus luteum deficiency.

Tralonide, a new topical steroid, can be used in atopic dermatitis.

Quinbolone is an anabolic steroid, developed by Parke-Davis, which was previously marketed in Italy. Quinbolone is a cyclopentenyl ether derivative of Boldenone (B675100) which is also its active metabolite. Quinbolone shows weak androgenic activity. Quinbolone didn`t have liver toxicity.

Trengestone is a steroid substance, a retroprogesterone. It has a strong progestogenic action and stimulating effect on the hypotalamo-hypophyseal system. It does not possess a direct oestrogenic or androgenic action. It indirectly stimulates the oestrogen productivity in the ovary via the central nervous system. The mechanism of action for induction of ovulation is not clear. It is indicated for the treatment of normooestrogenic anovulation. Ovulation occurs after trengestone administration either immediately ater termination of treatment or much later. Another indication for its administration are other functional disorders of the cycle and treatment of imminent abortion. Side-effects are: mastalgia, headache and fatigue.

Nomegestrol acetate (NOMAC) is a 19-norprogesterone derivative with high biological activity at the progesterone receptor, a weak anti-androgenic effect, but with no binding to estrogen, glucocorticoid or mineralocorticoid receptors. Nomegestrol has been developed by the Monaco-based company Théramex SAM (a Teva subsidiary). Nomegestrol acetate has been used successfully for the treatment of some gynaecological disorders (menstrual disturbances, dysmenorrhoea, premenstrual syndrome) and as a component of hormone replacement therapy in combination with estradiol for the relief of menopausal symptoms; it has been approved in Europe as monotherapy for the treatment of the menopausal syndrome, uterine diseases and menorrhagia, and in combination with an estrogen for the treatment of menopausal symptoms. Nomegestrol acetate in combination with estradiol is used as an oral contraceptive.

Paramethasone is a glucocorticoid. It exerts anti-inflammatory and immunosuppressant actions. Paramethasone stimulates the synthesis of enzymes needed to decrease anti-inflammatory response. It suppresses the immune system by reducing activity and volume of the lymphatic system, thus producing lymphocytopenia decreasing passage of immune complexes and possibly by depressing reactivity of tissue to antigen-antibody interactions.